利用佐剂驱动T细胞反应以研发新一代传染病疫苗
Using Adjuvants to Drive T Cell Responses for Next-Generation Infectious Disease Vaccines.
作者信息
Rapaka Rekha R, Cross Alan S, McArthur Monica A
机构信息
Center for Vaccine Development and Global Health, University of Maryland School of Medicine, 685 West Baltimore Street, Baltimore, MD 21201, USA.
出版信息
Vaccines (Basel). 2021 Jul 24;9(8):820. doi: 10.3390/vaccines9080820.
Abstract
Using adjuvants to drive features of T cell responses to vaccine antigens is an important technological challenge in the design of new and improved vaccines against infections. Properties such as T helper cell function, T cell memory, and CD8+ T cell cytotoxicity may play critical roles in optimal and long-lived immunity through vaccination. Directly manipulating specific immune activation or antigen delivery pathways with adjuvants may selectively augment desired T cell responses in vaccination and may improve the effectiveness and durability of vaccine responses in humans. In this review we outline recently studied adjuvants in their potential for antigen presenting cell and T cell programming during vaccination, with an emphasis on what has been observed in studies in humans as available.
摘要
使用佐剂来驱动针对疫苗抗原的T细胞应答特性，是设计新型和改良型抗感染疫苗的一项重要技术挑战。诸如辅助性T细胞功能、T细胞记忆和CD8+T细胞细胞毒性等特性，可能在通过疫苗接种实现最佳和持久免疫方面发挥关键作用。用佐剂直接操纵特定的免疫激活或抗原递送途径，可能在疫苗接种中选择性增强所需的T细胞应答，并可能提高人类疫苗应答的有效性和持久性。在本综述中，我们概述了最近研究的佐剂在疫苗接种期间对抗抗原呈递细胞和T细胞编程的潜力，重点是在现有人类研究中观察到的情况。
相似文献
1
Using Adjuvants to Drive T Cell Responses for Next-Generation Infectious Disease Vaccines.
Vaccines (Basel). 2021 Jul 24;9(8):820. doi: 10.3390/vaccines9080820.
2
Adjuvant-enhanced CD4 T Cell Responses are Critical to Durable Vaccine Immunity.
EBioMedicine. 2015 Nov 27;3:67-78. doi: 10.1016/j.ebiom.2015.11.041. eCollection 2016 Jan.
3
Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5α Restrictive Macaques.
J Virol. 2017 Jan 31;91(4). doi: 10.1128/JVI.01844-16. Print 2017 Feb 15.
4
Choice and Design of Adjuvants for Parenteral and Mucosal Vaccines.
Vaccines (Basel). 2015 Mar 5;3(1):148-71. doi: 10.3390/vaccines3010148.
5
Laser Adjuvant-Assisted Peptide Vaccine Promotes Skin Mobilization of Dendritic Cells and Enhances Protective CD8 T and T Cell Responses against Herpesvirus Infection and Disease.
J Virol. 2018 Mar 28;92(8). doi: 10.1128/JVI.02156-17. Print 2018 Apr 15.
6
Natural killer T cell and TLR9 agonists as mucosal adjuvants for sublingual vaccination with clade C HIV-1 envelope protein.
Vaccine. 2014 Dec 5;32(51):6934-6940. doi: 10.1016/j.vaccine.2014.10.051. Epub 2014 Nov 2.
7
Bovine immune response to leptospira antigen in different novel adjuvants and vaccine delivery platforms.
Vaccine. 2020 Apr 16;38(18):3464-3473. doi: 10.1016/j.vaccine.2020.02.086. Epub 2020 Mar 20.
8
Effective Respiratory CD8 T-Cell Immunity to Influenza Virus Induced by Intranasal Carbomer-Lecithin-Adjuvanted Non-replicating Vaccines.
PLoS Pathog. 2016 Dec 20;12(12):e1006064. doi: 10.1371/journal.ppat.1006064. eCollection 2016 Dec.
9
CD4+ Th-APC with acquired peptide/MHC class I and II complexes stimulate type 1 helper CD4+ and central memory CD8+ T cell responses.
J Immunol. 2009 Jan 1;182(1):193-206. doi: 10.4049/jimmunol.182.1.193.
10
Induction and direction of immune responses by vaccine adjuvants.
Crit Rev Immunol. 2001;21(1-3):75-85.
引用本文的文献
1
Immunological Responses to Tetanus and Influenza Vaccination in Donkeys.
J Vet Intern Med. 2025 Jul-Aug;39(4):e70137. doi: 10.1111/jvim.70137.
2
Beyond Needles: Immunomodulatory Hydrogel-Guided Vaccine Delivery Systems.
Gels. 2024 Dec 26;11(1):7. doi: 10.3390/gels11010007.
3
New COVID-19 vaccination recommendations in Spain: Optimizing for next seasons.
Enferm Infecc Microbiol Clin. 2025 Jan;43(1):36-46. doi: 10.1016/j.eimc.2024.08.012.
4
Structural Characterization and Immune Activation Capacity of Peptidoglycan from in RAW264.7 Cells.
Int J Mol Sci. 2024 Dec 30;26(1):237. doi: 10.3390/ijms26010237.
5
Senolytic Vaccines from the Central and Peripheral Tolerance Perspective.
Vaccines (Basel). 2024 Dec 10;12(12):1389. doi: 10.3390/vaccines12121389.
6
Drugs Targeting Sirtuin 2 Exhibit Broad-Spectrum Anti-Infective Activity.
Pharmaceuticals (Basel). 2024 Sep 29;17(10):1298. doi: 10.3390/ph17101298.
7
[Two cases of neonatal pneumonia].
Zhongguo Dang Dai Er Ke Za Zhi. 2024;26(9):986-988. doi: 10.7499/j.issn.1008-8830.2405123.
8
Crosstalking with Dendritic Cells: A Path to Engineer Advanced T Cell Immunotherapy.
Front Syst Biol. 2024;4. doi: 10.3389/fsysb.2024.1372995. Epub 2024 Apr 29.
9
Local Enrichment with Convergence of Enriched T-Cell Clones Are Hallmarks of Effective Peptide Vaccination against B16 Melanoma.
Vaccines (Basel). 2024 Mar 22;12(4):345. doi: 10.3390/vaccines12040345.
10
Vaccine adjuvants: current status, research and development, licensing, and future opportunities.
J Mater Chem B. 2024 May 1;12(17):4118-4137. doi: 10.1039/d3tb02861e.
本文引用的文献
1
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans.
Nature. 2021 Jul;595(7868):572-577. doi: 10.1038/s41586-021-03653-6. Epub 2021 May 27.
2
Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant.
N Engl J Med. 2021 May 20;384(20):1899-1909. doi: 10.1056/NEJMoa2103055. Epub 2021 May 5.
3
Immunogenicity and efficacy of one and two doses of Ad26.COV2.S COVID vaccine in adult and aged NHP.
J Exp Med. 2021 Jul 5;218(7). doi: 10.1084/jem.20202756.
4
Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial.
Lancet Infect Dis. 2021 Oct;21(10):1383-1394. doi: 10.1016/S1473-3099(21)00200-0. Epub 2021 Apr 19.
5
Ebola virus disease: current vaccine solutions.
Curr Opin Immunol. 2021 Aug;71:27-33. doi: 10.1016/j.coi.2021.03.008. Epub 2021 Apr 17.
6
SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice.
Nat Commun. 2021 Jan 14;12(1):372. doi: 10.1038/s41467-020-20653-8.
7
Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine.
N Engl J Med. 2021 May 13;384(19):1824-1835. doi: 10.1056/NEJMoa2034201. Epub 2021 Jan 13.
8
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.
Nat Med. 2021 Feb;27(2):270-278. doi: 10.1038/s41591-020-01194-5. Epub 2020 Dec 17.
9
COVID-19 vaccine BNT162b1 elicits human antibody and T1 T cell responses.
Nature. 2020 Oct;586(7830):594-599. doi: 10.1038/s41586-020-2814-7. Epub 2020 Sep 30.
10
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults.
N Engl J Med. 2020 Dec 17;383(25):2427-2438. doi: 10.1056/NEJMoa2028436. Epub 2020 Sep 29.
Zotero 插件